publication date: Mar. 21, 2014


Ashworth Named Center Director at UCSF

ALAN ASHWORTH was appointed director of the UCSF Helen Diller Family Comprehensive Cancer Center, effective January 2015.

Ashworth is chief executive of the Institute of Cancer Research in London. Together with its partner hospital, the Royal Marsden NHS Foundation Trust, the ICR is one of the top rated cancer centers globally.

Peter Carroll will serve as interim director, effective April 1. He is associate dean of the UCSF School of Medicine, chair of the UCSF Department of Urology, and leader of the prostate cancer program at the UCSF cancer center.

Ashworth succeeds Frank McCormick, an internationally renowned molecular biologist who helped pave the way toward the development of targeted cancer therapies.

McCormick has taken on a leadership role as director of the RAS Project, a laboratory of the NCI that will focus on the mutated protein that plays a key role in a third of all cancers. He will also remain as a faculty member in the UCSF cancer center.

Ashworth was part of the team that discovered the BRCA2 gene in 1995. A decade later, Ashworth identified a way to exploit genetic weaknesses in cancer cells, including mutated BRCA2, leading to a new approach to cancer therapy. In 2008, he was elected as a Fellow of the Royal Society.

Ashworth, who has been with the ICR for 28 years, is a professor of molecular biology and leader of the gene function team in The Breakthrough Breast Cancer Research Centre at the ICR. The ICR has continued to be a world leader in isolating cancer-related genes and discovering new targeted drugs for personalized cancer treatment. Since 2005, the … Continue reading 40-12 In Brief

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.